Potential usefulness of DNA methylation as a risk marker for digestive cancer associated with inflammation

Expert Review of Molecular Diagnostics

Volumn 12, Issue 5, 2012, Pages 489-497

  Tahara, Tomomitsu ^a   Arisawa, Tomiyasu ^b  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

digestive tract; DNA methylation; epigenetics; Helicobacter pylori; hepatitis B virus; hepatitis C virus; inflammation; ulcerative colitis

Indexed keywords

APC PROTEIN; CSPG2 PROTEIN; CYCLOOXYGENASE 2; DEATH ASSOCIATED PROTEIN KINASE; ER PROTEIN; FLICE INHIBITORY PROTEIN; FLNC PROTEIN; GLUTATHIONE TRANSFERASE P1; HAND1 PROTEIN; HIC 1 PROTEIN; LOX PROTEIN; MYOD1 PROTEIN; PROTEIN; PROTEIN MLH1; PROTEIN P14; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SUPPRESSOR OF CYTOKINE SIGNALING 1; THBD PROTEIN; THBS1 PROTEIN; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG; UVOMORULIN;

CANCER RISK; CPG ISLAND; DISEASE ASSOCIATION; DNA METHYLATION; HELICOBACTER INFECTION; HEPATITIS B; HEPATITIS C; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; REVIEW; STOMACH CANCER; ULCERATIVE COLITIS; ULCERATIVE COLITIS ASSOCIATED CANCER;

CARCINOMA, HEPATOCELLULAR; COLITIS, ULCERATIVE; DNA METHYLATION; GASTRITIS; GASTROINTESTINAL NEOPLASMS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION; LIVER NEOPLASMS; RISK FACTORS;

EID: 84862580013     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.12.38     Document Type: Review

References (98)

1. Ushijima T, Watanabe N, Okochi E, Kaneda A, Sugimura T, Miyamoto K. Fidelity of the methylation pattern and its variation in the genome. Genome Res. 13(5), 868-874 (2003) (Pubitemid 36621747)
2. Riggs AD, Xiong Z. Methylation and epigenetic fidelity. Proc. Natl Acad. Sci. USA 101(1), 4-5 (2004) (Pubitemid 38084192)
3. Fazzari MJ, Greally JM. Introduction to epigenomics and epigenome-wide analysis. Methods Mol. Biol. 620, 243-265 (2010)
4. Kondo Y. Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med. J. 50(4), 455-463 (2009)
5. Jones PA, Baylin SB. The epigenomics of cancer. Cell 128(9), 683-692 (2007) (Pubitemid 46273572)
6. Toyota M, Issa JP. Epigenetic changes in solid and hematopoietic tumors. Semin. Oncol. 32(5), 521-530 (2005)
7. Ushijima T, Okochi-Takada E. Aberrant methylations in cancer cells: where do they come from? Cancer Sci. 96(4), 206-211 (2005) (Pubitemid 40767056)
8. Suzuki H, Tokino T, Shinomura Y, Imai K, Toyota M. DNA methylation and cancer pathways in gastrointestinal tumors. Pharmacogenomics 9(12), 1917-1928 (2008)
9. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer 5(3), 223-231 (2005) (Pubitemid 40314953)
10. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96(15), 8681-8686 (1999) (Pubitemid 29354851)
11. Toyota M, Ahuja N, Suzuki H et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 59(21), 5438-5442 (1999) (Pubitemid 29526452)
12. Toyota M, Ohe-Toyota M, Ahuja N, Issa JP. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc. Natl Acad. Sci. USA 97(2), 710-715 (2000) (Pubitemid 30070374)
13. Kusano M, Toyota M, Suzuki H et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 106(9), 1467-1479 (2006)
14. Ahn JB, Chung WB, Maeda O et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 117(9), 1847-1854 (2011)
15. Jover R, Nguyen TP, Pérez-Carbonell L et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 140(9), 1174-1181 (2011)
16. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet. 7(4), 536-540 (1994) (Pubitemid 24308343)
17. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res. 58(23), 5489-5494 (1998) (Pubitemid 28551135)
18. Kwabi-Addo B, Chung W, Shen L et al. Age-related DNA methylation changes in normal human prostate tissues. Clin. Cancer Res. 13(13), 3796-3802 (2007) (Pubitemid 47037584)
19. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345(11), 784-789 (2001)
20. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med. 323(9)8, 1228-1233 (1990)
21. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48(9), 526-535 (2001) (Pubitemid 32234798)
22. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 48 SUPPL. 1, S20-S37 (2008)
23. Nakajima T, Maekita T, Oda I et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol. Biomarkers Prev. 15(11), 2317-2321 (2006) (Pubitemid 44877064)
24. Tahara T, Shibata T, Nakamura M et al. Increased number of CpG island hypermethylation in tumor suppressor genes of non-neoplastic gastric mucosa correlates with higher risk of gastric cancer. Digestion 82(9), 27-36 (2010)
25. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 61(9), 3573-3577 (2001) (Pubitemid 32694963)
26. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 47(9), 908-918 (2008) (Pubitemid 351449682)
27. Laird PW. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3(9), 253-266 (2003) (Pubitemid 37328861)
28. No authors listed. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 272(9), 65-69 (1994)
29. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 325(9)6, 1127-1131 (1991)
30. Huang JQ, Sridhar S, Chen Y et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 114(9), 1169-1179 (1998) (Pubitemid 28243902)
31. Blaser MJ, Parsonnet J. Parasitism by the 'slow' bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J. Clin. Invest. 94(9), 4-8 (1994)
32. Uemura N, Mukai T, Okamoto S et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol. Biomarkers Prev. 6(9), 639-642 (1997) (Pubitemid 27342688)
33. Wong BC, Lam SK, Wong WM et al. China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291(9), 187-194 (2004) (Pubitemid 38082812)
34. Hosokawa O, Tsuda S, Kidani E et al. Diagnosis of gastric cancer up to three years after negative upper gastrointestinal endoscopy. Endoscopy 30(9), 721-773 (1998)
35. Wang M, Furuta T, Takashima M et al. Relation between interleukin-1b messenger RNA in gastric fundic mucosa and gastric juice pH in patients infected with Helicobacter pylori. J. Gastroenterol. 34(SUPPL. 11), 10-17 (1999) (Pubitemid 30072480)
36. Yamaoka Y, Kita M, Kodama T, Sawai N, Kashima K, Imanishi J. Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains. Gut 41(9), 442-451 (1997)
37. Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J. Gastroenterol. 12(9), 192-198 (2006) (Pubitemid 43336916)
38. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. 61(9), 2847-2851 (2001) (Pubitemid 32691923)
39. Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH, Kim JS. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am. J. Pathol. 163(9), 1551-1556 (2003) (Pubitemid 37175101)
40. Maekita T, Nakazawa K, Mihara M et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin. Cancer. Res. 12(3 Pt 1), 989-995 (2006) (Pubitemid 43259882)
41. Tahara T, Arisawa T, Shibata T et al. Increased number of methylated CpG islands correlates with Helicobacter pylori infection, histological and serological severity of chronic gastritis. Eur. J. Gastroenterol. Hepatol. 21(9), 613-619 (2009)
42. Kaise M, Yamasaki T, Yonezawa J, Miwa J, Ohta Y, Tajiri H. CpG island hypermethylation of tumor-suppressor genes in H. pylori-infected non-neoplastic gastric mucosa is linked with gastric cancer risk. Helicobacter 13(9), 35-41 (2008)
43. Yamamoto E, Toyota M, Suzuki H et al. LINE-1 hypomethylation is associated with increased CpG island methylation in Helicobacter pylori-related enlarged-fold gastritis. Cancer Epidemiol. Biomarkers Prev. 17(9)0, 2555-2564 (2008)
44. Nakajima T, Enomoto S, Yamashita S et al. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J. Gastroenterol. 45(9), 37-44 (2010)
45. Head KA, Jurenka JS. Inflammatory bowel disease part I: ulcerative colitis - pathophysiology and conventional and alternative treatment options. Altern. Med. Rev. 8(9), 247-283 (2003) (Pubitemid 37099887)
46. Askling J, Dickman PW, Karlen P et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 120(9), 1356-1362 (2001) (Pubitemid 32322309)
47. Nuako KW, Ahlquist DA, Mahoney DW et al. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 115(9), 1079-1083 (1998) (Pubitemid 28485597)
48. Jayaram H, Satsangi J, Chapman RW. Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction? Gut 48(9), 430-434 (2001) (Pubitemid 32269576)
49. Rutter MD, Saunders BP, Wilkinson KH et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 53(9)2, 1813-1816 (2004) (Pubitemid 39556902)
50. Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, Porschen R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res. 58(9)7, 3942-3945 (1998) (Pubitemid 28405652)
51. Fleisher AS, Esteller M, Harpaz N et al. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res. 60(9)7, 4864-4868 (2000)
52. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 287(1), G7-G17 (2004) (Pubitemid 38802113)
53. Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126(2), 451-459 (2004) (Pubitemid 38182302)
54. Moriyama T, Matsumoto T, Nakamura S et al. Hypermethylation of p14 ARF may be predictive of colitic cancer in patients with ulcerative colitis. Dis. Colon. Rectum 50(9), 1384-1392 (2007) (Pubitemid 47472402)
55. Wang FY, Arisawa T, Tahara T et al. Aberrant DNA methylation in ulcerative colitis without neoplasia. Hepatogastroenterology 55(81), 62-65 (2008) (Pubitemid 351462164)
56. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 140(6), 1704-1712 (2011)
57. Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm. Bowel Dis. 17(3), 831-848 (2011)
58. Di Girolamo N, Visvanathan K, Lloyd A, Wakefield D. Expression of TNFa by human plasma cells in chronic inflammation. J. Leukoc. Biol. 61(6), 667-678 (1997) (Pubitemid 27276058)
59. Noguchi M, Hiwatashi N, Liu Z, Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut 43(2), 203-209 (1998) (Pubitemid 28348322)
60. Huang S, Ullrich SE, Bar-Eli M. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J. Interferon Cytokine Res. 19(7), 697-703 (1999) (Pubitemid 29379811)
61. Zimmerman NP, Vongsa RA, Wendt MK, Dwinell MB. Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm. Bowel Dis. 14(7), 1000-1011 (2008)
62. Bollrath J, Phesse TJ, von Burstin VA et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15(2), 91-102 (2009)
63. Grivennikov S, Karin E, Terzic J et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15(2), 103-113 (2009)
64. Konishi K, Shen L, Wang S, Meltzer SJ, Harpaz N, Issa JP. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology 132(4), 1254-1260 (2007) (Pubitemid 46627571)
65. Fujii S, Tominaga K, Kitajima K et al. Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis. Gut 54(9), 1287-1292 (2005) (Pubitemid 41192492)
66. Tominaga K, Fujii S, Mukawa K et al. Prediction of colorectal neoplasia by quantitative methylation analysis of estrogen receptor gene in nonneoplastic epithelium from patients with ulcerative colitis. Clin. Cancer Res. 11(24 Pt 1), 8880-8885 (2005) (Pubitemid 43005941)
67. Garrity-Park MM, Loftus EV Jr, Sandborn WJ, Bryant SC, Smyrk TC. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am. J. Gastroenterol. 105(7), 1610-1619 (2010)
68. Saito S, Kato J, Hiraoka S et al. DNA methylation of colon mucosa in ulcerative colitis patients: correlation with inflammatory status. Inflamm. Bowel Dis. 17(9), 1955-1965 (2011)
69. Tahara T, Shibata T, Nakamura M et al. Effect of MDR1 gene promoter methylation in patients with ulcerative colitis. Int. J. Mol. Med. 23(4), 521-527 (2009)
70. Tahara T, Shibata T, Nakamura M et al. Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). Clin. Exp. Med. 9(2), 125-130 (2009)
71. Neumann H, Vieth M, Langner C, Neurath MF, Mudter J. Cancer risk in IBD: how to diagnose and how to manage DALM and ALM. World J. Gastroenterol. 17(27), 3184-3191 (2011)
72. Feitelson MA. Parallel epigenetic and genetic changes in the pathogenesis of hepatitis virus-associated hepatocellular carcinoma. Cancer Lett. 239(1), 10-20 (2006) (Pubitemid 43949592)
73. Kondoh N, Wakatsuki T, Hada A et al. Genetic and epigenetic events in human hepatocarcinogenesis. Int. J. Oncol. 18(6), 1271-1278 (2001)
74. Boyault S, Rickman DS, De Reynies A et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45(1), 42-52 (2007) (Pubitemid 46144363)
75. Wong IH, Lo YM, Zhang J et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59(1), 71-73 (1999) (Pubitemid 29062959)
76. Zhang YJ, Ahsan H, Chen Y et al. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol. Carcinog. 35(2), 85-92 (2002)
77. Xiao WH, Liu WW. Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma. World J. Gastroenterol. 10(3), 376-380 (2004)
78. Kanai Y, Ushijima S, Hui AM et al. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int. J. Cancer 71(3), 355-359 (1997) (Pubitemid 27224296)
79. Zhong S, Tang MW, Yeo W, Liu C, Lo YM, Johnson PJ. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin. Cancer Res. 8(4), 1087-1092 (2002) (Pubitemid 35177360)
80. Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am. J. Pathol. 163(3), 1101-1107 (2003) (Pubitemid 37040145)
81. Shen L, Ahuja N, Shen Y et al. DNA methylation and environ mental exposures in human hepatocellular carcinoma. J. Natl Cancer Inst. 94(10), 755-761 (2002) (Pubitemid 34567960)
82. Iwata N, Yamamoto H, Sasaki S et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 s gene in human hepatocellular carcinoma. Oncogene 19(46), 5298-5302 (2000)
83. Kaneto H, Sasaki S, Yamamoto H et al. Detection of hypermethylation of the p16 (INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 48(3), 372-377 (2001) (Pubitemid 32269566)
84. Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 33(3), 561-568 (2001) (Pubitemid 32185217)
85. Su PF, Lee TC, Lin PJ et al. Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma. Int. J. Cancer 121(6), 1257-1264 (2007)
86. Jicai Z, Zongtao Y, Jun L, Haiping L, Jianmin W, Lihua H. Persistent infection of hepatitis B virus is involved in high rate of p16 methylation in hepatocellular carcinoma. Mol. Carcinog. 45(7), 530-536 (2006)
87. Park IY, Sohn BH, Yu E et al. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 132(4), 1476-1494 (2007) (Pubitemid 46627570)
88. Deng YB, Nagae G, Midorikawa Y et al. Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma. Cancer Sci. 101(6), 1501-1510 (2010)
89. Lim SO, Gu JM, Kim MS et al. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology 135(6), 2128-2140 (2008)
90. Hartnett L, Egan LJ. Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis 33(4), 723-731 (2012)
91. Ushijima T. Epigenetic field for cancerization. J. Biochem. Mol. Biol. 40(2), 142-150 (2007) (Pubitemid 46515191)
92. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques 35(1), 146-150 (2003) (Pubitemid 36828724)
93. Watanabe Y, Kim HS, Castoro RJ et al. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology 136(7), 2149-2158 (2009)
94. Kamimae S, Yamamoto E, Yamano HO et al. Epigenetic alteration of DNA in mucosal wash fluid predicts invasiveness of colorectal tumors. Cancer Prev. Res. (Phila.) 4(5), 674-683 (2011)
95. Shin CM, Kim N, Jung Y et al. Genome-wide DNA methylation profiles in noncancerous gastric mucosae with regard to Helicobacter pylori infection and the presence of gastric cancer. Helicobacter 16(3), 179-188 (2011)
96. Matsusaka K, Kaneda A, Nagae G et al. Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res. 71(23), 7187-7197 (2011)
97. Ando T, Yoshida T, Enomoto S et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int. J. Cancer 124(10), 2367-2374 (2009)
98. Suzuki H, Yamamoto E, Nojima M et al. Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis 31(12), 2066-2073 (2010).